Insmed Incorporated (INSM)
NASDAQ: INSM · Pharmaceutical Preparations · Bridgewater, NJ
Our rating: Cautious
Cautious reaffirmed at $112.58, moderate conviction, October 30, 2026.
Breaks if: The cautious view is wrong if, within the next six months, both patent invalidations are confirmed on the record — through appellate rulings, company disclosures, or filings — to cover only non-commercial or peripheral claims that do not affect the primary revenue-generating indication AND the next two reported quarterly revenues each show year-over-year growth above 55%; that combination would indicate the core commercial franchise remains legally protected and growth is not decelerating, materially changing the IP-risk and valuation calculus.
Key figures
| Market value | $31.0B |
|---|---|
| Revenue, last 12 months | $1.5B |
| Net income, last 12 months | −$606M |
| Free cash flow, last 12 months | −$628M |
| Price to earnings | n/a |
| Free cash flow yield | −2.0% |
| Dividend yield | 0.0% |
| Operating margin | −37.1% |
| Return on equity | −72.5% |
| Beta to the S&P 500 | 0.61 |
| Volatility, annualized | 93.6% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | $524M | 268.4% | $-0.46 | −$42M |
| June 30, 2026 | $425M | 296.1% | $-0.06 | −$95M |
| March 31, 2026 | $306M | 229.6% | $-0.76 | −$226M |
| December 31, 2025 | $264M | 152.6% | $-1.53 | −$264M |
| September 30, 2025 | $142M | 52.4% | $-1.75 | −$222M |
| June 30, 2025 | $107M | 18.9% | $-1.70 | −$209M |
| March 31, 2025 | $93M | 22.9% | $-1.42 | −$272M |
| December 31, 2024 | $104M | 24.8% | $-1.30 | −$203M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Revenue for the quarter is at least $0.89B: Claude 5%, Gemini 80%, Mistral 35%
- Diluted earnings per share are above zero: Claude 25%, Gemini 20%, Mistral 30%
- Free cash flow for the quarter is above zero: Claude 40%, Gemini 75%, Mistral 60%
26 ledger entries and 34 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.